IFNG and hemophagocytic syndrome: Emapalumab, a monoclonal antibody that targets IFN-γ, directly inhibits the interferon’s biological activity, thereby mitigating cytokine storms.[25] EBV-HLH presents a grave malady, necessitating prompt and accurate diagnosis coupled with proactive and holistic intervention strategies.